Center For Experimental Therapeutics
School of Medicine
University of Pennsylvania Health System
654 BRB II/III
421 Curie Blvd
Philadelphia, PA 19104
TEL: 215-573-4176
FAX: 215-573-8606

### **MEMORANDUM**

To:

Data Safety Monitoring Board Members

Peter Adamson, MD (Chair) Roger Illingworth, MD Frederick Nunes, MD

From:

Daniel J. Rader, MD

Date:

February 9, 2004

Re:

Data from 6 enrolled patients

Title:

A Phase II Open Label, Dose-Escalation Study to Determine the Safety, Tolerability and Efficacy of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor BMS-201038 in Patients with Homozygous Familial Hypercholesterolemia (Protocol No. UP 1001)

Please find enclosed the following appendices describing the available clinical data of 6 patients enrolled in the above reference protocol.

Appendix 1: Subject Demography at Baseline

Appendix 2: Extent of Exposure to Study Drug BMS-201038

Appendix 3: Vital Signs Listing

Appendix 4: Pulmonary Function Tests and NMRS/MRI of the Liver by Subject

Appendix 5: Listing of Adverse Events by Subject

Listing of All Reported Clinical and Laboratory Adverse Events

Appendix 6: Listing of Adverse Events by Event

Listing of All Reported Clinical and Laboratory Adverse Events


Appendix 7: Listing of Laboratory Parameters by Subject


Appendix 8: Percent Change in Total Cholesterol at the End of Each Treatment Dose Compared to Baseline Appendix 9: Percent Change in Non-HDL Cholesterol at the End of Each Treatment Dose Compared to Baseline Appendix 10: Percent Change in Apolipoprotein B at the End of Each Treatment Dose Compared to Baseline


Appendix 11: Fat Soluble Vitamins and Fatty Acid Profile in Subjects Receiving BMS-201038


Please do not hesitate to contact me if you have any questions or require additional information. We thank you for your time in serving on the DSMB for this study and are excited by the efficacy and reasonable tolerability of this MTP inhibitor compound in these homozygous FH patients.











# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

